Gilead expands lenacapavir licensing to cover once-yearly HIV prevention

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Gilead expands lenacapavir licensing to cover once-yearly HIV prevention

Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention

September 16, 2026 8:30 AM EDT

- 6 Royalty-Free Voluntary Licensing Agreements Aim to Support Potential Manufacturing Readiness and Supply in 120 High-Incidence, Resource-Limited Countries Ahead of Phase 3 PURPOSE 365 Results and Potential Regulatory Approvals -

- Builds On Gilead's Ongoing Commitment to Communities Affected by HIV by Helping Enable Broad, Sustainable Access to Lenacapavir for PrEP -

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to include investigational once-yearly lenacapavir for HIV prevention as... More